Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta …
H Liu, Y Wu, T Lv, Y Yao, Y Xiao, D Yuan, Y Song - PLoS one, 2013 - journals.plos.org
Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis …
F Petrelli, K Borgonovo, M Cabiddu, V Lonati, S Barni - Lung cancer, 2012 - Elsevier
BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data
E Dudnik, M Moskovitz, S Daher, S Shamai… - Lung cancer, 2018 - Elsevier
Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
B Tischer, R Huber, M Kraemer, ME Lacouture - Supportive care in cancer, 2017 - Springer
Purpose As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety
of dermatologic adverse events (dAEs), the purpose of this study was to develop an …
of dermatologic adverse events (dAEs), the purpose of this study was to develop an …
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced Non–Small-Cell lung cancer
Background Adherence to erlotinib could be a determinant for clinical outcome and
treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients …
treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients …
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway
Q Luo, Y Gu, W Zheng, X Wu, F Gong, L Gu… - Toxicology and applied …, 2011 - Elsevier
Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
M Tiseo, R Andreoli, F Gelsomino, P Mozzoni, C Azzoni… - Lung cancer, 2014 - Elsevier
Objectives An association between skin toxicity and outcome has been reported for NSCLC
patients treated with erlotinib. Several explanations have been suggested, including …
patients treated with erlotinib. Several explanations have been suggested, including …
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients
H Bai, B Han - American journal of clinical oncology, 2013 - journals.lww.com
Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments
C Gridelli, P Maione, MA Bareschino… - Anticancer …, 2010 - ar.iiarjournals.org
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …